Abstract

BackgroundThymic epithelial tumors (TETs) are rare tumors originating from the thymic epithelial cells. SOX9, a member of the family of SOX (SRY-related high-mobility group box) genes, has been considered as an oncogene and therapeutic target in various cancers. However, its role in TETs remains uncertain.MethodsUsing the immunohistochemistry method, the expression of SOX9 was analyzed in TETs tissues, including 34 thymoma (8 cases with type A, 6 with type AB, 6 with type B1, 9 with type B2, and 5 with type B3 thymomas) and 20 thymic cancer tissues and the clinicopathologic and prognostic significances were evaluated. Further bioinformatics analysis of gene expression profiles of thymomas with high and low SOX9 expressions and the corresponding survival analyses were based on the thymoma cases identified in The Cancer Genome Atlas (TCGA) database, with the median expression level of SOX9 selected as cutoff.ResultsImmunohistochemistry staining showed that SOX9 was highly expressed in the nuclei of the epithelial cells of the Hassall’s corpuscles and of the TET tumor cells. SOX9 expression was significantly associated with histological type and high expression indicated unfavorable clinical outcomes of thymomas. Bioinformatics analysis revealed that genes positively associated with SOX9 expression were mapped in proteoglycans in cancer, cell adhesion molecules, and molecules involved in extracellular matrix-receptor interaction and the TGF-β signaling pathway, and that genes negatively associated with SOX9 expression were mapped in molecules involved in primary immunodeficiency, the T cell receptor signaling pathway, Th17 cell differentiation, PD-L1 expression, and the PD-1 checkpoint pathway in cancer. In addition, SOX9 expression was positively associated with POU2F3 and TRPM5 expressions, the master regulators of tuft cells, suggesting that high SOX9 expression might be associated with the tuft cell phenotype of thymomas. Moreover, high SOX9 expression was associated with immune dysregulation of thymoma, and M2 macrophage significantly dominated in the high SOX9 expression group.ConclusionSOX9 may serve as a diagnostic and prognostic marker for TETs. Notably, high SOX9 expression in TETs may indicate a tuft cell phenotype and an immune suppressive microenvironment of thymomas.

Highlights

  • Thymic epithelial tumors (TETs), including thymomas and thymic carcinomas, are rare tumors of the mediastinum and originate from the thymic epithelial cells [1, 2]

  • To investigate the diagnostic significance of SRY-related high-mobility group box 9 (SOX9) in thymic tumors, immunohistochemistry staining of SOX9 expression was performed in 34 thymomas and 20 thymic carcinoma tissues

  • We found that SOX9 was expressed in the nuclei of the epithelial cells of Hassall’s corpuscles and in the epithelial component of TET cells in almost all cases

Read more

Summary

Introduction

Thymic epithelial tumors (TETs), including thymomas and thymic carcinomas, are rare tumors of the mediastinum and originate from the thymic epithelial cells [1, 2]. Most of thymic tumors are composed of non-malignantappearing thymic epithelial cells mixed with multiple proportions of lymphocytes, which makes it difficult to diagnose and predict the prognosis of thymic tumors [1]. According to the World Health Organization (WHO) classification, thymic epithelial cells are categorized into six subtypes, including A, AB, B1, B2, B3, and C ( known as TCs) based on histological appearance [3,4,5]. The exact pathologic diagnosis of TETs is essential for determining the treatment strategy and predicting the prognosis. Thymic epithelial tumors (TETs) are rare tumors originating from the thymic epithelial cells.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call